IOVA
Iovance Biotherapeutics, Inc. - Common Stock - Recent news and sentiment analysis
Default charts cover the last 24 hours by "day" period and sentiment shares compare positive vs. negative mentions after removing neutral posts.
Price
Today
Users
Total
IOVA Price & Sentiment Over Time
Sentiment series exclude neutral posts so the green/red balance matches the bar on the home page; price points use the latest available quote.
I’m ready to pass my IOVA bag to the next gen of bagholders.
I’m ready to pass my IOVA bag to the next gen of bagholders.
IOVA printing rn
Run IOVA run!!!
21500 shares of IOVA. LFG
Fuck, I got out of $IOVA too early, it pumped even more now
Fuck, I got out of $IOVA too early, it pumped even more now
IOVA bagholder here, still down on the position, stand by.
IOVA bagholder here, still down on the position, stand by.
IOVA Strong 25Q4 Earnings Call
They just had a stellar Q4 earnings. CEO said there was potential for a 10-12B market cap ($60). Several catalysts still in the bag due in 26/27. Back to back to back Quarter improvement for their FDA approved product. Not selling a single share until at least $35.
Iova brrrr 💸
IOVA! IOVA! IOVA!!!
IOVA take me to heavens
IOVA take me to heavens
IOVA better than IBRX
IOVA better than IBRX
IOVA lol
Help me IOVA you’re my only hope
Help me IOVA you’re my only hope
Lets fuckin gooo IOVA
Let’s go IOVA!!! Beat earnings this morning!
Let’s go IOVA!!! Beat earnings this morning!
IOVA
IOVA earnings opinions?
"the FDA is shifting its default policy to require only **one** adequate and well-controlled clinica...
"the FDA is shifting its default policy to require only **one** adequate and well-controlled clinical study for new drug approvals, dropping the long-standing two-study standard." Lowkey biotech might be the play here. has recovered some but still pretty damn cheap since agent orange took office. Lot of room to run up potentially I like IOVA and CRSP but XBI is the easy bet
Melanoma was already cured by IOVA
Melanoma was already cured by IOVA
wtf, IOVA has a 35% short interest.
wtf, IOVA has a 35% short interest.
Told you guys about this gem a month ago. 20K up, and I’m not going to sell a single share until SP is $35.. 2026 is going to explosive beginning with 25Q4 in Feb with several catalyst coming up. Thesis still remains intact and with several analyst re rating, and trading strongly above the 50 SMA, 21 EMA and most importantly the 200 SMA further solidifying this uptrend, breakout is clear and there is no signs of slow down despite the high SI of about 120m share (35%) of the float This is a millionaire make stock and I’m excited AF, get in before it starts its meteoric rise. I have previously made a DD on this gem and it all is still relevant. https://www.reddit.com/r/wallstreetbets/s/tu4lTRZ85t
IOVA flying high again?!!?
Another day for IOVA?
Why is IOVA running today?
IOVA?
IOVA DD: Best in class Cancer Drug
I am writing this on my phone. So forgive me for any typos or formatting mistakes. What IOVA does? Iovance Biotherapeutics is the first company to get an FDA approval for a cell therapy that works in solid tumors. (Roughly over 90%, remaining 10% being Blood) Their product, Amtagvi (lifileucel), is a one-time TIL therapy (tumor-infiltrating lymphocytes). Doctors take T cells from the tumor, Iovance expands them into billions, and those cells get infused back into the patient. Very intuitive, essentially using our own bodies cells to fight cancer. Melanoma patients who failed everything else can now get a therapy that produces real, durable responses. This is the first real proof that cell therapy can work outside blood cancers. Recently 5 year real world data was released and it only strengthened its proof that the drug works. I hold 30,000 shares. 2) Why This Is Actually Big Solid tumors are the majority of cancer deaths. You may have heard of CAR-T but that doesn’t work on them. They only work for blood cancer which is only 10% of TAM, rest being Soldin tumor cancer. Chemo and immunotherapy are the current 1L treatment, and 2L severely lacking treatment. If TIL therapy becomes a category across multiple cancers, the market is massive. Melanoma alone is 1 billion USD. Add cervical, NSCLC, head and neck, ovarian: the upside gets wide quickly. In fact the pipeline already includes ongoing trials for all of the above indications, with several already in late stage phase 3. The biggest one being NSCLC which is notorious in the oncology space for being one of the hardest cancer to treat. And Amtagvi is kicking ass in this area. With the recent early results indicating that they are the best in class drug with over 2 times better efficacy across all metrics with current best in class treatment. NSCLC itself is at least 5 billion USD market IOVA has the head start in this space. No other TIL player is even close to where IOVA is. They have their own manufacturing facilities that’s worth 1 billion USD itself. 3) Sales Are Actually Real Amtagvi launch started in mid-2024. Early numbers: • Q2: around $31M • Q3: around $62M Over 100 patients treated in a single quarter. 70+ treatment centers active or onboarding. Revenue guidance for 2025 is around the 250-300M range. And management has reiterated their range for EOY. For a ~$1B market cap company, that’s extremely low valuation. 3) Bear Case arguments that don’t hold water Execution: With IOVA bears and shorts never questioned the science but about the execution. I will admit that execution in Q1 has been terrible. However, they bought in a new CFO (Corleen Roche) in Q3 and she had already improved margin by 40% in Q3 alone along with several other improvements planned for Q4 Adoption: This was another pain point, during the early days and up until Q2 for IOVA. Since, it is a Novel treatment. Patient referrals by Doctors was slow, and they had to figure out the logistics part of the process. In Q3 IOVA has teamed up with McKesson (The biggest healthcare distribution and services company in the world specializing in Novel therapies). The benefit from this partnership will be reflected in Q4 earnings and they continue to setup more ATCs and train up staff. Q4 will be explosive. Upcoming Catalysts These matter far more than the long essays analysts write: 1. Quarterly revenue beats Sales are ramping fast. If they keep beating, the market re-rates this quickly. Recently after Q3 earnings several analyst have rerated already to high target. Q4 will be huge for this stock 2. New indications Cervical cancer filing potential. NSCLC Lung cancer data updates for FDA approval First-line melanoma combo with Keytruda in Phase 3. 3. Global approvals EMA and UK reviews underway. (UK is already approved but not announced) Canada already approved. 4. Manufacturing improvements Shorter turnaround time = more patients = more revenue. 5. Buyout potential If the tech proves generalizable, any major pharma would want this platform. 2026 will establish IOVANCE as a platform for TIL therapy Long-Term Bull Case If TIL therapy works across multiple tumors, this becomes the cell therapy platform for solid cancers. The total addressable market becomes enormous. At least $30B and at current share prices that’s $75 per share. Even if you are super bear about this stock at $10 minimum is already better than its current price. Q4 will be the breaking point for this stock. First-in-class advantage, strong early sales, a huge melanoma market, and a pipeline that expands into larger cancers. If they execute, this isn’t a 5 percent upside story. It’s potentially several multiples. This is why I’m long 30K shares. Risks Not sugarcoated: • Manufacturing is complex. • Treatment is intensive for patients but they are already developing less intensive treatment without the need for Interlukin 2 • Reimbursement must stay strong. Currently have cash till 2027 H1 • Trials outside melanoma can fail. But highly unlikely given its recent data release. It’s incredible • Volatility is brutal. Shorts have been at this stock with about 35% shorted. However, about 80-90% is owned by Institutions. Big names like Blackrock, GS , etc.. • They’ve diluted before and might again if sales don’t scale fast enough. But this is expected and normal in Biotech You don’t buy this thinking it’s a safe biotech. You buy it because the upside outweighs the risks. And the upside heavily outweighs the risks Bottom Line IOVA has the first approved TIL therapy, real revenue, growing adoption, a pipeline aiming at much bigger cancers, and a valuation priced like it’s dead. I’m long 30K shares because this is one of the few biotechs where the science, the market, and the timing actually line up. If they deliver on the next 12–24 months of catalysts, this has legitimate multi-bagger potential. Q4 will be turning point. Get in before the stock rips. It will create generational wealth. If you want an actual shot at a big biotech move that isn’t complete vapor, this is one of the few worth watching.
IOVA is breaking out.
IOVA and SOC
IOVA is about to blow up! Load it up!
IOVA is about to blow up! Load it up!
Continuing holding IOVA, I’m up 43% Might as well continue to ride the momentum.
Continuing holding IOVA, I’m up 43% Might as well continue to ride the momentum.
IOVA to the fcking moon
IOVA is happening
IOVA TO 3 upside after that watching heavily for volatility swings
IOVA TO 3 upside after that watching heavily for volatility swings
Holy shit IOVA
IOVA thoughts!?
IOVA $2.25, sold at $2.45 6000 shares. Not too bad
IOVA $2.25, sold at $2.45 6000 shares. Not too bad
I went all in on IOVA a couple days ago, seems like I’d be better off just holding.
I went all in on IOVA a couple days ago, seems like I’d be better off just holding.
$iova short squeeze will cure cancer forever
$iova short squeeze will cure cancer forever
Anyone else here enjoying the IOVA ride?
Anyone else here enjoying the IOVA ride?
IOVA :)
IOVA!!!!
IOVA!
IOVA beat earnings! Climb! Climb! Climb!
IOVA beat earnings! Climb! Climb! Climb!
Let’s go IOVA!!!
Whos holding iova for tomorrow earnings?
Whos holding iova for tomorrow earnings?
Whoever made that DD on IOVA, your moms a hoe. I’m down almost $1k
Whoever made that DD on IOVA, your moms a hoe. I’m down almost $1k
I always buy IOVA when it dips below $2.00 and it shot up to $2.49 when I sold. Nice little profit.
I always buy IOVA when it dips below $2.00 and it shot up to $2.49 when I sold. Nice little profit.
IOVA
IOVA